• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Edwards Lifesciences Announces CFO Transition Plan

    10/30/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care
    Get the next $EW alert in real time by email

    Edwards Lifesciences (NYSE:EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role.

    About Edwards Lifesciences

    Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.

    This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as "may," "might," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "goal," "continue," "seek," "intend," "optimistic," "aspire," "confident" and other forms of these words and include, but are not limited to, statements regarding the plan to transition Mr. Ullem, including the timing of the transition, and the transition goals of enabling continuity and a smoother transfer, as well as Mr. Ullem continuing in an advisory role and other statements that are not historical facts . Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.

    Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.

    Edwards, Edwards Lifesciences, and the stylized E logo, are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251030455357/en/

    Media Contact: Amy Meshulam, 949-250-4009

    Investor Contact: Mark Wilterding, 949-250-6826

    Get the next $EW alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EW

    DatePrice TargetRatingAnalyst
    11/3/2025$96.00Mkt Perform → Outperform
    Raymond James
    10/29/2025Underperform → Peer Perform
    Wolfe Research
    10/29/2025$98.00Hold → Buy
    Jefferies
    10/8/2025Outperform → Perform
    Oppenheimer
    10/7/2025$88.00In-line → Outperform
    Evercore ISI
    7/29/2025$100.00Neutral → Buy
    BTIG Research
    4/24/2025$80.00Neutral → Overweight
    Piper Sandler
    1/30/2025$75.00 → $90.00Hold → Buy
    Stifel
    More analyst ratings

    $EW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Edwards Lifesciences upgraded by Raymond James with a new price target

    Raymond James upgraded Edwards Lifesciences from Mkt Perform to Outperform and set a new price target of $96.00

    11/3/25 9:08:28 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by Wolfe Research

    Wolfe Research upgraded Edwards Lifesciences from Underperform to Peer Perform

    10/29/25 7:48:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by Jefferies with a new price target

    Jefferies upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $98.00

    10/29/25 7:47:49 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edwards Lifesciences Announces CFO Transition Plan

    Edwards Lifesciences (NYSE:EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are insp

    10/30/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Reports Third Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights Q3 sales grew 14.7% to $1.55 billion, or 12.6% adjusted1, with strength across all product groups Q3 TAVR sales grew 12.4%; constant currency1 sales grew 10.6% Q3 TMTT sales of $145.2 million, growth driven by PASCAL and EVOQUE Q3 EPS of $0.502; adjusted1 EPS of $0.67 SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling long-term outcomes equivalent to surgery at 7 years, further supported by 10-year follow-up of PARTNER 2 studies New ESC/EACTS guidelines simplify care pathways for all severe AS patients EVOQUE real-world da

    10/30/25 4:13:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Successful Patient Outcomes Demonstrated With Edwards' SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025

    ENCIRCLE mitral trial achieves primary and secondary endpoints EVOQUE tricuspid valve registry demonstrates more favorable outcomes than pivotal trial Edwards Lifesciences (NYSE:EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and secondary endpoints for safety and effectiveness, with outcomes simultaneously published in The Lancet. Thirty-day data from the EVOQUE system STS/ACC TVT Registry, the largest real-world transcatheter tricuspid valve replacement (TTVR) dataset, outperformed results from the TRISCEND II pivotal trial. These d

    10/27/25 3:06:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    SEC Filings

    View All

    SEC Form 10-Q filed by Edwards Lifesciences Corporation

    10-Q - Edwards Lifesciences Corp (0001099800) (Filer)

    11/5/25 4:12:51 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Corporation filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Edwards Lifesciences Corp (0001099800) (Filer)

    10/30/25 4:29:32 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Edwards Lifesciences Corp (0001099800) (Filer)

    10/30/25 4:18:04 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zovighian Bernard J covered exercise/tax liability with 4,245 shares, converted options into 6,265 shares and bought $49,753 worth of shares (580 units at $85.74), increasing direct ownership by 5% to 46,836 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    5/7/24 5:53:27 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 262 shares, decreasing direct ownership by 3% to 7,927 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    9/15/25 6:44:47 PM ET
    $EW
    Industrial Specialties
    Health Care

    CVP, TMTT & Surgical Chopra Daveen was granted 3,205 shares, increasing direct ownership by 10% to 34,201 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    9/15/25 6:44:45 PM ET
    $EW
    Industrial Specialties
    Health Care

    CVP, JAPAC Markowitz Wayne was granted 6,410 shares and covered exercise/tax liability with 650 shares, increasing direct ownership by 47% to 18,146 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    9/15/25 6:42:44 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Leadership Updates

    Live Leadership Updates

    View All

    Edwards Lifesciences Announces CFO Transition Plan

    Edwards Lifesciences (NYSE:EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are insp

    10/30/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

    SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE:EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR)—a transformative therapy now recognized as one of the most suc

    8/25/25 4:33:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

    Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positive

    3/6/25 8:00:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Financials

    Live finance-specific insights

    View All

    Edwards Lifesciences Reports Third Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights Q3 sales grew 14.7% to $1.55 billion, or 12.6% adjusted1, with strength across all product groups Q3 TAVR sales grew 12.4%; constant currency1 sales grew 10.6% Q3 TMTT sales of $145.2 million, growth driven by PASCAL and EVOQUE Q3 EPS of $0.502; adjusted1 EPS of $0.67 SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling long-term outcomes equivalent to surgery at 7 years, further supported by 10-year follow-up of PARTNER 2 studies New ESC/EACTS guidelines simplify care pathways for all severe AS patients EVOQUE real-world da

    10/30/25 4:13:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025

    Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended September 30, 2025 after the market closes on Thursday October 30, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinici

    10/23/25 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Reports Second Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and EVOQUE Q2 EPS of $0.572; adjusted1 EPS of $0.67 SAPIEN platform is only TAVR approved for asymptomatic patients in U.S. and now in Europe EuroPCR data confirm clinical and economic advantages of timely treatment for severe AS patients 10-year data from PARTNER II study confirm long-term outcomes and durability

    7/24/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Edwards Lifesciences Corporation

    SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)

    11/8/24 10:34:33 AM ET
    $EW
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Edwards Lifesciences Corporation

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    10/4/24 2:14:28 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    2/13/24 5:04:42 PM ET
    $EW
    Industrial Specialties
    Health Care